Skip to main content

Table 2 Unmet need

From: Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration

Factors

Unresolved issues

Comments

Patient factors

Non-adherence and/or non-compliance

Patient education and better understanding of disease and therapy

Cost of therapy/visits

Individual healthcare jurisdiction cost and reimbursement policies

High individual treatment burden

Need for more durable agents

Poor prognosis

Need for more efficacious agents or regenerative therapies to reverse damage by nAMD

Therapeutic factors

Relatively short duration of action resulting in repeated treatments

Need for more durable agents

Poor efficacy resulting in persistently active disease

Need for more efficacious agents

Safety profile

Need for better preclinical safety models that can provide early safety signals before entry into clinical practice

Healthcare system factors

High treatment burden to society

Combination of more durable and efficacious agents may help address this unmet need by preventing/reversing blindness from nAMD

Reimbursement and subsidies

Individual healthcare jurisdiction cost and reimbursement policies

Increasing patient load

Need for more durable agents and/or more precise therapies to minimise unnecessary monitoring visits